Adult liver transplantation: What non-specialists need to know

BMJ (Online)

Volumn 338, Issue 7706, 2009, Pages 1321-1327

  Hirschfield, G M ^a   Gibbs, P ^b   Griffiths, W J H ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN A; FLUCONAZOLE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ATYPICAL INFECTION; BONE MARROW SUPPRESSION; CARDIOVASCULAR RISK; CHRONIC GRAFT REJECTION; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; FUNGEMIA; GENERAL PRACTITIONER; GUM HYPERTROPHY; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHY; INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPHOMA; NEPHROTOXICITY; NEUROPATHY; OSTEOPOROSIS; PANCREATITIS; PATIENT ASSESSMENT; PATIENT CARE; PNEUMOCYSTOSIS; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEIZURE; SERUM SICKNESS; SIDE EFFECT; VEIN OCCLUSION; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

ADULT; FAMILY PRACTICE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; NURSE'S ROLE; PATIENT SELECTION; PHYSICIAN'S ROLE; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME; WAITING LISTS;

EID: 67650045432     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b1670     Document Type: Review

References (30)

1. Transplant UK. UK transplant activity report, 2007-08. www.uktransplant.org.uk/ukt/statistics/transplant-activity-report/ transplant-activity-report.jsp.
2. Dawwas MF, Gimson AE, Lewsey JD, Copley LP, van der Meulen JH. Survival after liver transplantation in the United Kingdomand Ireland compared with the United States. Gut 2007;56:1606-13.
3. Pomfret EA, Fryer JP, Sima CS, Lake JR, Merion RM. Liver and intestine transplantation in the United States, 1996-2005. Am J Transplant 2007;7:1376-89.
4. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
5. KimWR, Biggins SW, KremersWK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl JMed 2008;359:1018-26.
6. Neuberger J, Gimson A, Davies M, Akyol M, O'Grady J, Burroughs A, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008;57:252-57.
7. Freeman RBJ, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L, et al. Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations fromthe MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2008;12:S128-36.
8. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-27.
9. Samuel D, Weber R, Stock P, Duclos-Vallée JC, Terrault N. Are HIV-infected patients candidates for liver transplantation? J Hepatol 2008;48:697-707.
10. Brown RSJ. Live donors in liver transplantation. Gastroenterology 2008;134:1802-13.
11. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008;8:667-72.
12. van der Meulen JH, Lewsey JD, Dawwas MF, Copley LP. Adult orthotopic liver transplantation in the United Kingdom and Ireland between 1994 and 2005. Transplantation 2007;84:572-9.
13. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008;8:419-25.
14. Freeman RBJ. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology 2008;47:1052-7.
15. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356:1545-59.
16. Ghobrial RM, Freise CE, Trotter JF, Tong L, Ojo AO, Fair JH, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008;135:468-76.
17. Hodson EM, Craig JC, Strippoli GF, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008;2:CD003774.
18. Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006;25:549-61.
19. Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, et al. Transmission of rabies virus froman organ donor to four transplant recipients. N Engl J Med 2005;352:1103-11.
20. Rosen HR. Transplantation immunology: what the clinician needs to know for immunotherapy. Gastroenterology 2008;134:1789-801.
21. Schmeding M, Sauer IM, Kiessling A, Pratschke J, Neuhaus R, Neuhaus P, et al. Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. Ann Transplant 2007;12:15-21.
22. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002;360:1119-25.
23. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006;4:CD005161.
24. Desai R, Jamieson NV, Gimson AE, Watson CJ, Gibbs P, Bradley JA, et al. Quality of life up to 30 years following liver transplantation. Liver Transpl 2008;14:1473-79.
25. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008;14:S36-44.
26. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.
27. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or =5 years after liver transplant. Transplantation 2000;69:781-89.
28. Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007;13:136-44.
29. Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998;4:285-96.
30. Fung JJ, Jain A, Kwak EJ, Kusne S, Dvorchik I, Eghtesad B. De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl 2001;7:S109-18.